S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
Log in

Amgen Stock Forecast, Price & News

+4.09 (+1.65 %)
(As of 01/20/2021 12:00 AM ET)
Today's Range
Now: $252.36
50-Day Range
MA: $231.21
52-Week Range
Now: $252.36
Volume2.65 million shs
Average Volume2.56 million shs
Market Capitalization$146.92 billion
P/E Ratio20.35
Dividend Yield2.58%
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease. It also markets other products in various markets, including Nplate, Vectibix, Repatha, Parsabiv, BLINCYTO, Aimovig, NEUPOGEN, Otezla, AMGEVITA, KANJINTI, EVENITY, IMLYGIC, MVASI, and Corlanor. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; QIAGEN N.V.; Adaptive Biotechnologies; and Eli Lilly and Company, as well as has a strategic agreement with McKesson Corporation to help improve cancer care in community oncology settings. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Amgen logo


Overall MarketRank

2.26 out of 5 stars

Medical Sector

20th out of 1,928 stocks

Biological Products, Except Diagnostic Industry

2nd out of 177 stocks

Analyst Opinion: 2.3Community Rank: 3.0Dividend Strength: 2.5Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:AMGN



Sales & Book Value

Annual Sales$23.36 billion
Cash Flow$19.44 per share
Book Value$16.28 per share


Net Income$7.84 billion


Market Cap$146.92 billion
Next Earnings Date2/2/2021 (Confirmed)
+4.09 (+1.65 %)
(As of 01/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Amgen (NASDAQ:AMGN) Frequently Asked Questions

How has Amgen's stock price been impacted by COVID-19 (Coronavirus)?

Amgen's stock was trading at $198.65 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AMGN stock has increased by 27.0% and is now trading at $252.36.
View which stocks have been most impacted by COVID-19

Is Amgen a buy right now?

30 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 1 sell rating, 12 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Amgen stock.
View analyst ratings for Amgen
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Amgen?

Wall Street analysts have given Amgen a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Amgen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Amgen's CEO?

1,428 employees have rated Amgen CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Amgen's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Amgen's next earnings date?

Amgen is scheduled to release its next quarterly earnings announcement on Tuesday, February 2nd 2021.
View our earnings forecast for Amgen

How can I listen to Amgen's earnings call?

Amgen will be holding an earnings conference call on Tuesday, February 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) issued its quarterly earnings data on Monday, November, 2nd. The medical research company reported $4.37 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $3.75 by $0.62. The medical research company earned $6.42 billion during the quarter, compared to analysts' expectations of $6.38 billion. Amgen had a net margin of 29.42% and a return on equity of 95.55%.
View Amgen's earnings history

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen announced a quarterly dividend on Wednesday, December 16th. Stockholders of record on Monday, February 15th will be given a dividend of $1.76 per share on Monday, March 8th. This represents a $7.04 annualized dividend and a yield of 2.79%. The ex-dividend date of this dividend is Thursday, February 11th. This is a positive change from Amgen's previous quarterly dividend of $1.60.
View Amgen's dividend history

Is Amgen a good dividend stock?

Amgen pays an annual dividend of $6.40 per share and currently has a dividend yield of 2.58%. Amgen does not yet have a strock track record of dividend growth. The dividend payout ratio of Amgen is 43.18%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Amgen will have a dividend payout ratio of 37.65% next year. This indicates that Amgen will be able to sustain or increase its dividend.
View Amgen's dividend history.

What guidance has Amgen issued on next quarter's earnings?

Amgen issued an update on its FY20 earnings guidance on Wednesday, October, 28th. The company provided EPS guidance of $15.80-16.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $15.78. The company issued revenue guidance of $25.1-25.5 billion, compared to the consensus revenue estimate of $25.39 billion.

What price target have analysts set for AMGN?

30 brokerages have issued 12-month target prices for Amgen's stock. Their forecasts range from $185.00 to $304.00. On average, they anticipate Amgen's share price to reach $255.88 in the next twelve months. This suggests a possible upside of 1.4% from the stock's current price.
View analysts' price targets for Amgen
or view Wall Street analyst' top-rated stocks.

Who are some of Amgen's key competitors?

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), The Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and The Home Depot (HD).

Who are Amgen's key executives?

Amgen's management team includes the following people:
  • Mr. Robert A. Bradway, Chairman, CEO & Pres (Age 57, Pay $5.61M)
  • Mr. Jonathan P. Graham, Exec. VP, Gen. Counsel & Sec. (Age 59, Pay $2.44M)
  • Dr. David M. Reese M.D., Exec. VP of R&D (Age 57, Pay $2.54M)
  • Mr. Murdo Gordon, Exec. VP of Global Commercial Operations (Age 53, Pay $2.66M)
  • Mr. Peter H. Griffith, Exec. VP & CFO (Age 61)
  • Mr. Esteban Santos, Exec. VP of Operations (Age 52)
  • Ms. Linda H. Louie, VP of Fin. & Chief Accounting Officer
  • Mr. Mike Zahigian, Sr. VP & Chief Information Officer
  • Mr. Arvind Sood, VP of Investor Relations
  • Nancy A. Grygiel, Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Who are Amgen's major shareholders?

Amgen's stock is owned by many different institutional and retail investors. Top institutional shareholders include Sarasin & Partners LLP (0.18%), Bartlett & Co. LLC (0.07%), Gateway Investment Advisers LLC (0.04%), Cullinan Associates Inc. (0.03%), Boston Trust Walden Corp (0.03%) and State of Alaska Department of Revenue (0.02%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams and Ronald D Sugar.
View institutional ownership trends for Amgen

Which institutional investors are selling Amgen stock?

AMGN stock was sold by a variety of institutional investors in the last quarter, including RNC Capital Management LLC, Pacer Advisors Inc., State of Alaska Department of Revenue, Exchange Traded Concepts LLC, Transform Wealth LLC, American National Bank, Pinnacle Financial Partners Inc., and Huntington National Bank. Company insiders that have sold Amgen company stock in the last year include David Piacquad, R Sanders Williams, and Ronald D Sugar.
View insider buying and selling activity for Amgen
or view top insider-selling stocks.

Which institutional investors are buying Amgen stock?

AMGN stock was acquired by a variety of institutional investors in the last quarter, including Sarasin & Partners LLP, Crossmark Global Holdings Inc., Chesley Taft & Associates LLC, Louisiana State Employees Retirement System, Oak Harvest Investment Services, Boston Trust Walden Corp, Wedge Capital Management L L P NC, and Bennicas & Associates Inc..
View insider buying and selling activity for Amgen
or or view top insider-buying stocks.

How do I buy shares of Amgen?

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $252.36.

How big of a company is Amgen?

Amgen has a market capitalization of $146.92 billion and generates $23.36 billion in revenue each year. The medical research company earns $7.84 billion in net income (profit) each year or $14.82 on an earnings per share basis. Amgen employs 23,400 workers across the globe.

What is Amgen's official website?

The official website for Amgen is www.amgen.com.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.